Impact of <i>Clostridioides difficile</i> Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
Vancomycin is frequently used for the treatment of <i>C. difficile</i> infections (CDI). There are concerns that this might increase the risk of selecting vancomycin resistant enterococci (VRE). Here, we evaluated whether there is an increased risk of VRE acquisition following vancomycin...
Guardado en:
Autores principales: | Carlos L. Correa-Martínez, Niklas C. J. Hagemeier, Neele J. Froböse, Stefanie Kampmeier |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/19921aa1bb474ee3adf18d88cd120d7b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
<i>Clostridioides difficile</i> and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Kateřina Bogdanová, et al.
Publicado: (2021) -
Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine
por: Abukhalil AD, et al.
Publicado: (2021) -
Informing Stewardship Measures in Canadian Food Animal Species through Integrated Reporting of Antimicrobial Use and Antimicrobial Resistance Surveillance Data—Part I, Methodology Development
por: Agnes Agunos, et al.
Publicado: (2021) -
Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates
por: Tilman G. Schultze, et al.
Publicado: (2021) -
Impact of a division-wide bundle on hospitalacquired Clostridioides difficile cases, antibiotic days of therapy, testing appropriateness, and associated financial costs
por: Elizabeth Wenqian Wang, et al.
Publicado: (2021)